• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织型纤溶酶原激活剂(tPA)抑制纤溶酶对纤维蛋白的降解。该机制可减缓tPA介导的纤维蛋白溶解,但不需要α2-抗纤溶酶或内源性纤溶酶原的泄漏。

Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

作者信息

Wu J H, Diamond S L

机构信息

Department of Chemical Engineering, State University of New York at Buffalo 14260, USA.

出版信息

J Clin Invest. 1995 Jun;95(6):2483-90. doi: 10.1172/JCI117949.

DOI:10.1172/JCI117949
PMID:7769094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC295930/
Abstract

Thrombolysis is dramatically slower when high concentrations of lytic agent are used. This paradoxical observation, first described as "plasminogen steal," was originally believed to be due to depletion of extrinsic plasminogen and consequent leaching of clot-bound plasminogen. We report that administration of increasing concentrations of recombinant human tissue plasminogen activator (tPA) to fibrin gels resulted in lysis rates that displayed a maximum, with significantly slower rates found at higher tPA, regardless of whether plasminogen was supplied extrinsically or intrinsically. A similar maximum in lysis rates was observed in a system lacking an extrinsic phase when plasminogen was added to fibrin suspensions preincubated with increasing tPA. Thus, intrinsic plasminogen leakage and alpha 2-antiplasmin were not required for the decreased lysis at high tPA. No maximum was observed for increasing concentrations of urokinase. Using fibrin suspensions or gels preincubated with tPA before addition of plasmin, we report that tPA, but not urokinase, caused a dose-dependent inhibition of the fibronolytic action of plasmin. With respect to optimal dosage schemes and the design of novel lytic agents, these findings indicate that (a) there exists a biochemical mechanism against minimizing reperfusion time with increasing tPA dosages and (b) the fibrin affinity of tPA may cause reduced fibrinolysis by plasmin.

摘要

当使用高浓度的溶栓剂时,溶栓速度会显著减慢。这一矛盾的观察结果最初被描述为“纤溶酶原窃取”,最初认为是由于外源性纤溶酶原的消耗以及随后与凝块结合的纤溶酶原的浸出所致。我们报告称,向纤维蛋白凝胶中加入浓度不断增加的重组人组织型纤溶酶原激活剂(tPA)会导致溶解速率出现最大值,在更高的tPA浓度下速率显著减慢,无论纤溶酶原是外源性供应还是内源性供应。当将纤溶酶原添加到预先用不断增加的tPA孵育的纤维蛋白悬浮液中时,在缺乏外源性阶段的系统中也观察到了类似的溶解速率最大值。因此,在高tPA浓度下溶解减少并不需要内源性纤溶酶原泄漏和α2-抗纤溶酶。对于不断增加的尿激酶浓度,未观察到最大值。在添加纤溶酶之前,使用预先用tPA孵育的纤维蛋白悬浮液或凝胶,我们报告称tPA而非尿激酶会导致纤溶酶的纤溶作用出现剂量依赖性抑制。关于最佳给药方案和新型溶栓剂的设计,这些发现表明:(a)存在一种生化机制,可防止随着tPA剂量增加而将再灌注时间减至最短;(b)tPA对纤维蛋白的亲和力可能会导致纤溶酶介导的纤维蛋白溶解减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f780/295930/cab7e7aafbb4/jcinvest00027-0071-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f780/295930/cab7e7aafbb4/jcinvest00027-0071-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f780/295930/cab7e7aafbb4/jcinvest00027-0071-a.jpg

相似文献

1
Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.组织型纤溶酶原激活剂(tPA)抑制纤溶酶对纤维蛋白的降解。该机制可减缓tPA介导的纤维蛋白溶解,但不需要α2-抗纤溶酶或内源性纤溶酶原的泄漏。
J Clin Invest. 1995 Jun;95(6):2483-90. doi: 10.1172/JCI117949.
2
Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.荧光素标记的纤维蛋白原和纤维蛋白有助于在充分混合的条件下进行大分子组装以及对皮摩尔水平的纤溶酶原激活剂进行动态检测。
Thromb Haemost. 1995 Aug;74(2):711-7.
3
Plasma fibronectin enhances fibrinolytic system in vitro.血浆纤连蛋白在体外增强纤溶系统。
Thromb Haemost. 1985 Oct 30;54(3):639-44.
4
Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.锌通过减弱纤溶酶原激活和纤溶酶介导的纤维蛋白降解来延迟血凝块溶解。
Thromb Haemost. 2015 Jun;113(6):1278-88. doi: 10.1160/TH14-09-0771. Epub 2015 Mar 19.
5
[Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].[急性肺血栓栓塞症溶栓治疗中纤溶酶-α2纤溶酶抑制物复合物及FDP.D二聚体水平的测定]
Kokyu To Junkan. 1992 Jul;40(7):685-90.
6
Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.健康与疾病中的纤维蛋白溶解:系统性红斑狼疮中的严重异常
J Lab Clin Med. 1984 Dec;104(6):962-76.
7
Extrinsic plasminogen activator: a new principle in fibrinolysis.外源性纤溶酶原激活剂:纤维蛋白溶解的新原理。
Behring Inst Mitt. 1983 Aug(73):43-55.
8
A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.纤维蛋白D片段和E-2片段对组织型纤溶酶原激活物及尿激酶原诱导的纤溶酶原激活作用的促进作用的比较研究
J Clin Invest. 1991 Dec;88(6):2012-7. doi: 10.1172/JCI115528.
9
Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.吸血蝙蝠唾液纤溶酶原激活剂可在血浆环境中促进血浆凝块的强力溶解,而不会引起液相纤溶酶原激活。
Thromb Haemost. 1992 Aug 3;68(2):165-9.
10
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.

引用本文的文献

1
Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.微米级组织型纤溶酶原激活剂(tPA)微珠可增强纤溶酶生成,用于强化溶栓治疗。
Bioeng Transl Med. 2025 Mar 3;10(4):e70012. doi: 10.1002/btm2.70012. eCollection 2025 Jul.
2
Harnessing micrometer-scale tPA beads for high plasmin generation and accelerated fibrinolysis.利用微米级组织型纤溶酶原激活剂(tPA)微珠实现高纤溶酶生成和加速纤维蛋白溶解。
bioRxiv. 2024 Nov 8:2024.11.06.621942. doi: 10.1101/2024.11.06.621942.
3
Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment.

本文引用的文献

1
ASSAY OF PLASMA THROMBOLYTIC ACTIVITY WITH FLUORESCEIN-LABELED CLOTS.用荧光素标记凝块测定血浆溶栓活性
J Lab Clin Med. 1964 Aug;64:313-20.
2
Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn2+ mediates strong and specific interaction of single-chain urokinase with fibrin.尿激酶型纤溶酶原激活剂的纤维蛋白亲和力。锌离子介导单链尿激酶与纤维蛋白强烈且特异性相互作用的证据。
J Biol Chem. 1993 Apr 25;268(12):8574-9.
3
Inner clot diffusion and permeation during fibrinolysis.纤维蛋白溶解过程中的内部凝块扩散与渗透。
影响重组组织型纤溶酶原激活剂疗效的因素:对缺血性脑卒中治疗的启示。
PLoS One. 2024 Jun 6;19(6):e0302269. doi: 10.1371/journal.pone.0302269. eCollection 2024.
4
Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study.危重病患者纤维蛋白溶解抵抗的即时诊断和监测:一项可行性研究的结果。
Crit Care. 2023 Feb 10;27(1):55. doi: 10.1186/s13054-023-04329-5.
5
Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.微滚轮共递送组织型纤溶酶原激活物和纤溶酶原以突破纤溶速度限制。
J Thromb Haemost. 2022 Feb;20(2):486-497. doi: 10.1111/jth.15617. Epub 2021 Dec 19.
6
Efficacy of Sonothrombolysis Using Microbubbles Produced by a Catheter-Based Microfluidic Device in a Rat Model of Ischemic Stroke.基于导管微流控装置产生的微泡的声溶栓在大鼠缺血性脑卒中模型中的疗效。
Ann Biomed Eng. 2019 Apr;47(4):1012-1022. doi: 10.1007/s10439-019-02209-0. Epub 2019 Jan 28.
7
Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements.针对血脑屏障(BBB)的治疗方法,脑血管疾病溶栓治疗的先决条件——综述与进展
AAPS PharmSciTech. 2015 Apr;16(2):223-33. doi: 10.1208/s12249-015-0287-z. Epub 2015 Jan 23.
8
The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies.组织纤溶酶原激活物结构域与纤维蛋白结构在纤溶调节中的相互作用:动力学和微观研究。
Blood. 2011 Jan 13;117(2):661-8. doi: 10.1182/blood-2010-06-290338. Epub 2010 Oct 21.
Biophys J. 1993 Dec;65(6):2622-43. doi: 10.1016/S0006-3495(93)81314-6.
4
The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.α2-抗纤溶酶和纤溶酶原激活物抑制剂1(PAI-1)在抑制血凝块溶解中的作用。
Thromb Haemost. 1993 Aug 2;70(2):301-6.
5
Lipoprotein (a) regulates plasmin generation and inhibition.脂蛋白(a)调节纤溶酶的生成与抑制。
Chem Phys Lipids. 1994 Jan;67-68:363-8. doi: 10.1016/0009-3084(94)90158-9.
6
Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.传输现象与血栓溶解疗法:扩散控制和渗透增强纤维蛋白溶解的实验研究
Thromb Haemost. 1994 Jul;72(1):105-12.
7
A fluorescence quench and dequench assay of fibrinogen polymerization, fibrinogenolysis, or fibrinolysis.一种用于纤维蛋白原聚合、纤维蛋白原溶解或纤维蛋白溶解的荧光猝灭和去猝灭测定法。
Anal Biochem. 1995 Jan 1;224(1):83-91. doi: 10.1006/abio.1995.1011.
8
The binding of human plasminogen to fibrin and fibrinogen.人纤溶酶原与纤维蛋白及纤维蛋白原的结合。
J Biol Chem. 1983 Apr 10;258(7):4249-56.
9
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.人组织型纤溶酶原激活剂cDNA在大肠杆菌中的克隆与表达。
Nature. 1983 Jan 20;301(5897):214-21. doi: 10.1038/301214a0.
10
Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.纤维蛋白的初始纤溶酶降解作为纤维蛋白溶解中正向反馈机制的基础。
Eur J Biochem. 1984 May 2;140(3):513-22. doi: 10.1111/j.1432-1033.1984.tb08132.x.